ArticleBlood advances2022
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- [External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.Cancer · 2025Observational
- Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes.Annals of hematology · 2025Review
- Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.Haematologica · 2024Article
- AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.Cancer reports (Hoboken, N.J.) · 2023Article
- Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future.Journal of clinical medicine · 2023Review
- Article
- Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.